BX Swiss TOP 30 CHF
1.252,95
PKT
+4,01
PKT
+0,32
%
Werbung
Analysen zu BX Swiss TOP 30 CHF-Werten
Datum | Rating | Analyst | |
---|---|---|---|
21.04.05 | Nestlé Neutral | Sarasin Research | |
21.04.05 | Roche Sector Outperform | Vontobel | |
22.04.05 | Novartis Kaufen | Helaba Trust | |
21.04.05 | Novartis Buy | Merrill Lynch | |
21.04.05 | Novartis Akkumulieren | Independent Research | |
20.04.05 | Logitech In-Line | Goldman Sachs | |
20.04.05 | Nestlé Overweight | JP Morgan | |
20.04.05 | Roche Buy | Sarasin Research | |
21.04.05 | Logitech Neutral | Sarasin Research | |
20.04.05 | Nestlé In-Line | Goldman Sachs | |
20.04.05 | Roche Overweight | JP Morgan | |
20.04.05 | ABB (Asea Brown Boveri) Kaufen | Helaba Trust | |
20.04.05 | Nestlé Kaufen | Helaba Trust | |
20.04.05 | Roche Outperform | Goldman Sachs | |
20.04.05 | Roche Equal weight | Lehman Brothers | |
21.04.05 | Novartis Underperform | Credit Suisse First Boston | |
19.04.05 | ABB (Asea Brown Boveri) Overweight | JP Morgan | |
19.04.05 | Roche Akkumulieren | Independent Research | |
19.04.05 | Novartis Buy | Merrill Lynch | |
19.04.05 | Roche Halten | Helaba Trust | |
19.04.05 | Roche Buy | Sarasin Research | |
18.04.05 | UBS Market Outperform | Vontobel | |
18.04.05 | Novartis Outperform | Goldman Sachs | |
19.04.05 | Roche Equal weight | Lehman Brothers | |
18.04.05 | UBS Market Perform | Vontobel | |
19.04.05 | Novartis Neutral | JP Morgan | |
19.04.05 | Roche Overweight | JP Morgan | |
18.04.05 | Nestlé Neutral | Sarasin Research | |
18.04.05 | Novartis Neutral | HypoVereinsbank | |
18.04.05 | Roche Buy | Helvea | |
15.04.05 | Novartis Kaufen | Helaba Trust | |
18.04.05 | Roche Outperform | HypoVereinsbank | |
18.04.05 | Novartis Neutral | Sarasin Research | |
15.04.05 | Roche In-Line | Goldman Sachs | |
18.04.05 | Roche Buy | Sarasin Research | |
15.04.05 | Roche In-Line | Goldman Sachs | |
14.04.05 | Novartis Reduce | UBS | |
14.04.05 | Novartis Reduce | UBS | |
14.04.05 | ABB (Asea Brown Boveri) Overweight | Lehman Brothers | |
14.04.05 | Roche Halten | Helaba Trust |